US manufacturer of generic medicines MYLAN LABORATORIES will be buying out KING PHARMACEUTICALS in a share exchange transaction valued at USD 4 bn. Under he agreement, KING shareholders will receive 0.9 of a MYLAN common share. The annual turnover estimated for the two entities for the last tax year was around USD 3 bn, with a workforce of 6000.